drugset
drugset / Trial / NCT03394118

TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy

NCT03394118 ↗

Phase 2 Completed 63 enrolled Asan Medical Center AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

In this trial, anti-tumor efficacy of TAGRISSO in NSCLC patients in whom T790 mutations are detected by liquid biopsy.

Timeline

Start
2017-08-11
Primary completion
2021-03-11
Completion
2021-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Osimertinib Small molecule 80 mg Oral

Indications

non-small cell lung carcinoma